Director Richard Peters Receives Equity Awards at Aprea Therapeutics

This Form 4 filing reports that Richard Peters, a director of Aprea Therapeutics, Inc. (APRE), received equity awards on June 16, 2026. He was granted 3,135 restricted stock units (RSUs) that will vest and settle in common stock on June 16, 2027, subject to continued board service. Additionally, he received stock option rights to purchase 12,555 shares at an exercise price of $0.7293 per share, which also vest on June 16, 2027. Both awards are subject to acceleration under certain conditions. Following these transactions, Peters holds 6,254 common shares directly and 12,555 stock options. The filing was signed by attorney-in-fact John Hamill on June 17, 2026.